FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective.

The article focuses on the Food and Drug Administration approval of lecanemab an anti-Aβ drug for the treatment of Alzheimer's disease. Topics include the efficacy and consistent evidence of lecanemab in reducing amyloid burden and slowing cognitive decline, as well as the implications of its approval for the use of amyloid Positron emission tomography in Europe.